Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF versus rhG-CSF for prevention of neutropenia during dose-dense adjuvant EC-T chemotherapy in early breast cancer
ChiCTR1900021105Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in neutropenia and febrile neutropenia (FN) comparing PEG-rhG-CSF group with rhG-CSF group (2 arms). Primary endpoint: Incidence of febrile neutropenia. Started Oct 2017; status: recruiting.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR1900021105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021105.